FLORIANA, Malta, Sept. 30, 2025 /PRNewswire/ -- ArriTech today announced the next generation of QGen Online, its software platform that enables businesses to build compliant onboarding without code, bringing AI-powered KYC, KYB, AML, and biometrics into a single flow.
QGen Online equips compliance, risk, and operations teams with a single, powerful platform to design, automate, and audit global onboarding processes. By streamlining workflows across jurisdictions, QGen Online accelerates market expansion while strengthening risk controls and reducing operational costs. Uniquely, ArriTech combines advanced automation with the expertise of people, a highly trained team of analysts, delivering both speed and the assurance of human oversight. The advanced technology of QGen Online was a key reason why entrepreneur Adrian Kreter made the strategic decision to acquire the company QGen in 2018, now rebranded as ArriTech.
"QGen Online is the foundation of ArriTech's mission to deliver seamless, secure onboarding for businesses worldwide," commented Philip Bugeja, CEO of ArriTech. "This next generation of technology brings KYC, KYB, AML, and biometrics together in a single platform, enabling companies to minimise risk, reduce false positives, and onboard customers faster."
Adopted across finance, fintech, and e-commerce amongst other industries, QGen online, assured by the expert analysts of ArriTech, supports 15,000+ ID types in 252 countries and integrates via REST APIs, webhooks, and a Web SDK for fast implementation. Recent enhancements include ISO 30107-3 certified passive liveness detection, dual-script AML screening, and direct KYB registry checks enabling clients to stay compliant while improving customer experience.
"Over the past six years, ArriTech has been a trusted, reliable partner, consistently delivering with professionalism, integrity, attention to detail, prompt responsiveness, deep expertise, and a collaborative approach that reflects the highest standards." Corina Bianca Leban COO, Vertex
With QGen Online, customers have reported reducing onboarding times by over 50% and cutting fraud attempts significantly. Further, the no-code workflows and built-in monitoring give customers full control without adding complexity.
ArriTech will release its 2025 Compliance & Fraud Risk Insights Report early in 2026 providing analysis of emerging fraud tactics, regulatory changes, and compliance best practices. For more information, www.arritech.com
About ArriTech
ArriTech's mission is to protect businesses and strengthen confidence by delivering advanced KYC, KYB, and AML solutions that ensure compliance, mitigate risks, and prevent fraud across global industries. With QGen, ArriTech combines automation with human expertise to help businesses streamline onboarding, reduce costs, and stay ahead of regulatory complexity.
www.arritech.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ArriTech Announces Its Next-Generation QGen Online Platform for No-Code, AI-Driven KYC, KYB, AML & Biometrics
|
Accomplished medical research leader will oversee NCCN programs to advance clinical trials and improve the quality, effectiveness, and accessibility of cancer care.
PLYMOUTH MEETING, Pa., April 9, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers devoted to patient care, research, and education—announced the selection of Nancy L. Lewis, MD, MBS, FACP, as new Chief Scientific Officer (CSO).
Dr. Lewis is an experienced biomedical researcher with expertise in clinical trials for treating solid tumors and hematologic malignancies. She most recently served as Senior Clinical Program Leader for Novartis Pharmaceuticals, after several years as an Associate Professor for various prestigious academic cancer centers. She holds degrees from Penn State University, Temple University School of Medicine, and Rutgers University. Dr. Lewis completed residency at the University of Rochester and Fellowship at Fox Chase Cancer Center—one of NCCN's founding Member Institutions.
"This is a pivotal time for cancer research; there are many successes to build on yet so much still to do. Dr. Lewis is the perfect person to oversee the work we do to foster innovation and knowledge discovery that improves the lives of people with cancer," said Crystal S. Denlinger, MD, CEO, NCCN. "She will be an important asset to our leadership team as she helps us ensure our research and clinical programs continue to advance outcomes in oncology around the world."
Dr. Lewis has previously been honored with awards from some of the foremost cancer organizations across the country, including the American Association for Cancer Research (AACR), The American Society of Clinical Oncology (ASCO), and the American Cancer Society (ACS).
As CSO, Dr. Lewis will assist in the NCCN Oncology Research Program (ORP) as well as key aspects of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Guidelines for Patients®. She will have oversight of the NCCN Biomarkers Compendium®; NCCN Radiation Therapy Compendium™, and NCCN Imaging Appropriate Use Criteria™. Dr. Lewis will also assist with NCCN's Continuing Medical Education Program and with relevant global and policy initiatives.
"I am thrilled to join the National Comprehensive Cancer Network and contribute to its extraordinary legacy of advancing high‑quality cancer care," said Dr. Lewis. "I look forward to working with NCCN's exceptional collaborators to tackle emerging challenges and drive innovative solutions that improve the lives of patients everywhere."
Dr. Lewis will succeed Dr. Denlinger who previously held the position of CSO before becoming CEO for the organization. Dr. Lewis will assume her new role in May 2026.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org
Accomplished medical research leader will oversee NCCN programs to advance clinical trials and improve the quality, effectiveness, and accessibility of cancer care.
PLYMOUTH MEETING, Pa., April 9, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers devoted to patient care, research, and education—announced the selection of Nancy L. Lewis, MD, MBS, FACP, as new Chief Scientific Officer (CSO).
Dr. Lewis is an experienced biomedical researcher with expertise in clinical trials for treating solid tumors and hematologic malignancies. She most recently served as Senior Clinical Program Leader for Novartis Pharmaceuticals, after several years as an Associate Professor for various prestigious academic cancer centers. She holds degrees from Penn State University, Temple University School of Medicine, and Rutgers University. Dr. Lewis completed residency at the University of Rochester and Fellowship at Fox Chase Cancer Center—one of NCCN's founding Member Institutions.
"This is a pivotal time for cancer research; there are many successes to build on yet so much still to do. Dr. Lewis is the perfect person to oversee the work we do to foster innovation and knowledge discovery that improves the lives of people with cancer," said Crystal S. Denlinger, MD, CEO, NCCN. "She will be an important asset to our leadership team as she helps us ensure our research and clinical programs continue to advance outcomes in oncology around the world."
Dr. Lewis has previously been honored with awards from some of the foremost cancer organizations across the country, including the American Association for Cancer Research (AACR), The American Society of Clinical Oncology (ASCO), and the American Cancer Society (ACS).
As CSO, Dr. Lewis will assist in the NCCN Oncology Research Program (ORP) as well as key aspects of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Guidelines for Patients®. She will have oversight of the NCCN Biomarkers Compendium®; NCCN Radiation Therapy Compendium™, and NCCN Imaging Appropriate Use Criteria™. Dr. Lewis will also assist with NCCN's Continuing Medical Education Program and with relevant global and policy initiatives.
"I am thrilled to join the National Comprehensive Cancer Network and contribute to its extraordinary legacy of advancing high‑quality cancer care," said Dr. Lewis. "I look forward to working with NCCN's exceptional collaborators to tackle emerging challenges and drive innovative solutions that improve the lives of patients everywhere."
Dr. Lewis will succeed Dr. Denlinger who previously held the position of CSO before becoming CEO for the organization. Dr. Lewis will assume her new role in May 2026.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Nancy L. Lewis, MD, MBS, FACP, Named New Chief Scientific Officer for National Comprehensive Cancer Network (NCCN)
